anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The Perioperative Outcome Risk Assessment with Computer Learning Enhancement (Periop ORACLE) study will be a sub-study nested within the ongoing TECTONICS trial (NCT03923699). TECTONICS is a single-center randomized clinical trial assessing the impact of an anesthesiology control tower (ACT) on postoperative 30-day mortality, delirium, respiratory failure, and acute kidney injury. As part of the TECTONICS trial, investigators in the ACT perform medical record case reviews during the early part of surgery and document how likely they feel each patient is to experience postoperative death and acute kidney injury (AKI). In Periop ORACLE, these case reviews will be randomized to be performed with or without access to machine learning (ML) predictions.

Investigators in the ACT will conduct all case reviews by viewing the patient's records in AlertWatch (AlertWatch, Ann Arbor, MI) and Epic (Epic, Verona, WI). AlertWatch is an FDA-approved patient monitoring system designed for use in the operating room. The version of AlertWatch used in this study has been customized for use in a telemedicine setting. Epic is the electronic health record system utilized at Barnes-Jewish Hospital. Each case review will be randomized in a 1:1 fashion to be completed with or without ML assistance. If the case review is randomized to ML assistance, the investigator will access a display interface (currently deployed as a web application on a secure server) that shows real-time ML predicted likelihood for postoperative death and postoperative AKI. If the case review is not randomized to ML assistance, the investigator will not access this display. After viewing the patient's data, the investigator will predict how likely the patient is to experience postoperative death and postoperative AKI and will document this prediction. The area under the receiver operating characteristic curves for predictions made with ML assistance and without ML assistance will be compared.
This invention provides an isolated nucleic acid molecule which encodes a wild-type or mutated SEL-10. This invention also provides a purified wild-type SEL-10 protein or a purified mutated SEL-10 protein. This invention also provides a method for production of an antibody capable of binding to wild-type SEL-10 or mutated SEL-10 protein. This invention also provides an antibody capable of specifically binding to wild-type SEL-10 or mutated SEL-10. This invention also provides a transgenic animal comprising the isolated nucleic molecule encoding SEL-10. This invention also provides a method for identifying a compound which is capable of ameliorating Alzheimer's disease. This invention also provides a method for determining whether a compound is capable of ameliorating Alzheimer's disease. This invention further provides a method for identifying a compound which is capable of treating cancer. This invention also provides a method for determining whether a compound is capable of treating cancer. This invention also provides a method for identifying a suppressor or enhancer that affects lin-12 or sel-12 activity in the same manner as sel-10. This invention also provides a method for producing suppressors of a sel-10 allele. This invenetion also provides a method for reversing the malignant phenotype of cells. This invention also provides a pharmaceutical composition effective in ameliorating Alzheimer's disease and treating cancer and methods of using such a pharmaceutical composition.
An extract of an Achillea sp. plant, an insoluble precipitate thereof and an active fraction thereof are provided to inhibit replication of hepatitis B virus and be non-toxic, thereby being usefully used as a pharmaceutical composition for preventing and treating hepatitis B virus. A pharmaceutical composition for preventing and treating hepatitis comprises an extract of an Achillea sp. plant, an insoluble precipitate generated by dissolving the extract in a lower alcohol, or an active fraction isolated from the insoluble precipitate using chromatography, wherein the Achillea sp. plant is selected from the group consisting of Achilla ptarmica subsp. macrocephala var. angustifolia Heim, Achillea acuminata (Lebeb.) Sch. Bio, Achillea acuminata Freyn, Achillea alpina L., Achillea alpina subsp. rhodoptarmica (Nakai) Kitam, Achillea alpina var, discoidea (Regal) Kitam, Achillea millefolium L., Achillea millefolium var. setacea (Waldst & Koch), Achillea ptarmica L., Achillea ptarmica var. acuminata (Ledeb.) Heim, Achillea ptarmicoides Naxim., Achilla rhodoptarmica Nakai, Achilla setacea Waldst & Kit, Achillea sibirica Ledet., and Achillea sibirica Var. discoidea Regal. Further, an extract solvent of the extract of the Achillea sp. plant is water, alcohol or a mixture thereof.
No overdoses of rizatriptan benzoate tablets were reported during clinical trials in adults. Some adult patients who received 40 mg of rizatriptan benzoate tablets either a single dose or as two doses with a 2-hour interdose interval had dizziness and somnolence.

In a clinical pharmacology study in which 12 adult subjects received rizatriptan benzoate tablets, at total cumulative doses of 80 mg (given within four hours), two of the subjects experienced syncope, dizziness, bradycardia including third degree AV block, vomiting, and/or incontinence.

In the long-term, open label study, involving 606 treated pediatric migraineurs 12 to 17 years of age (of which 432 were treated for at least 12 months), 151 patients (25%) took two 10-mg doses of rizatriptan benzoate orally disintegrating tablets within a 24- hour period. Adverse reactions for 3 of these patients included abdominal discomfort, fatigue, and dyspnea.

In addition, based on the pharmacology of rizatriptan benzoate tablets, hypertension or myocardial ischemia could occur after overdosage. Gastrointestinal decontamination, (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with rizatriptan benzoate tablets. Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed.

The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.
A light emitting diode (LED) balancing circuit is configured for balancing current flowing through a LED circuit. The LED balancing circuit includes a first transistor, a second transistor, a current limiting resistor, and a detecting resistor. A collector of the first transistor connects to the LED circuit. A base of the second transistor connects to an emitter of the first transistor. A collector of the second transistor connects to a base of the first transistor. An emitter of the second transistor connects to a ground. The current limiting resistor connects the base of the first resistor to a power source and is configured for providing voltage for the first transistor. One end of the detecting resistor connects to the emitter of the first transistor and the base of the second transistor. The other end of the detecting resistor connects to the ground. A LED driving circuit using the LED balancing circuit is also provided.
The Foundational Helping Skills training will be intervention to be evaluated in this study. The Foundational Helping Skills is a flexible curriculum, with an approximate 3-day (20 hour) duration to be modified based on context and personnel. The Foundational Helping Skills is a human-centered design competency-based training in foundational helping skills. The training curriculum has been developed in a modular format, with each module relating to specific foundational helping skills (e.g., non-verbal communication, confidentiality, etc). The training curriculum can be found. The general training outline includes two days of foundational helping skill modules, brief role-play competency assessments at the end of each foundational helping skills training day to inform trainers which competencies need remediation, and a half-day of training that involves a remediation of the specific foundational helping skills that have been identified via the brief role-play assessments.
It is proposed the use of genetic therapy for cirrhotic livers by means of the specific transmission of the gene of the human urokinase plasminogen activator or (huPA), which activates mechanisms to induce the matrix extracellular excess degradation and stimulates the hepatocytes proliferation, accomplishing with this a fast reestablishment of liver functionality. In the present it was utilized the human gene uPA modified and inserted in the adenoviral vector (pAd-huPA), which is not secreted and does not produce hypo-coagulation or internal spontaneous bleedings; likewise data from the study in bio-distribution with an adenoviral vector with the reporter gene b-gal, has shown the specificity of the liver as target organ of the vector. It was detected the huPA protein by ELISA in liver homogenates (4500 pg/ml) in animals injected with pAd-huPA) and it was also intracellularly detected by immune-histochemical process in liver cuts (80% of positive cells). The huPA caused a dramatic red uction of fibrosis (85% at the 10th day of administrating the vector, compared with control cirrhotic rats and a hepatocytes proliferation of 55%. The hepatic functional tests (ALT, AST, alkaline phosphatase and bilirubin) diminished almost up to normal levels and the hepatocytes proliferation was verified. Due to the two cascades of beneficial events, the gene therapy with the huPA modified can be developed as a definitive potential treatment in patients with hepatic cirrhosis.
Double-J (DJ) stents are most commonly used urological tools these days. Serious complications may occur when stents are left in place for longer duration. We present a case of a woman in her 40s with a forgotten DJ stent for 4 years, leading to complications such as encrustations, bladder and renal stone formation. The patient underwent a comprehensive endourological approach, including endoscopic cystolithotomy and left-sided percutaneous nephrolithotomy. The case highlights the importance of timely stent removal to prevent complications such as encrustations and stone formation. Patient education and counselling are crucial to avoid poor compliance and the associated risks of forgotten stents. This case underscores the significance of a multidisciplinary approach and emphasises the need for proactive measures to prevent such complications, including the implementation of a stent placement registry.
The doses in the table are those considered to be necessary to produce a successful block and should be regarded as guidelines for use in adults. Individual variations in onset and duration occur. The figures reflect the expected average dose range needed. For other local anesthetic techniques standard current textbooks should be consulted. 

When prolonged blocks are used, either through continuous infusion or through repeated bolus administration, the risks of reaching a toxic plasma concentration or inducing local neural injury must be considered. Experience to date indicates that a cumulative dose of up to 770 mg NAROPIN administered over 24 hours is well tolerated in adults when used for postoperative pain management: i.e., 2016 mg. Caution should be exercised when administering NAROPIN for prolonged periods of time, e.g., >70 hours in debilitated patients. 

For treatment of postoperative pain, the following technique can be recommended: If regional anesthesia was not used intraoperatively, then an initial epidural block with 5 to 7 mL NAROPIN is induced via an epidural catheter. Analgesia is maintained with an infusion of NAROPIN, 2 mg/mL (0.2%). Clinical studies have demonstrated that infusion rates of 6 to 14 mL (12 to 28 mg) per hour provide adequate analgesia with nonprogressive motor block. With this technique a significant reduction in the need for opioids was demonstrated. Clinical experience supports the use of NAROPIN epidural infusions for up to 72 hours.
PURPOSE: To explore the distribution and prevalence of osteoarthritis in metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints in long fingers in a cadaveric study, and to discuss potential biomechanical influences on these patterns.
METHODS: This cadaveric study evaluated 144 metacarpophalangeal, proximal interphalangeal and distal interphalangeal joints from 12 embalmed cadaver hands. A dorsal dissection approach was used to expose the joints, which were then marked with color-coded pegs for consistent orientation during imaging. High-resolution digital images of the distal articular surfaces were captured for analysis. The images were analyzed using custom software to quantify osteoarthritic areas, distinguishing between radial and ulnar aspects. Percentage affected joint surface was calculated using pixel-based measurements. Statistical analysis was used the Student t-test and ANOVA, with the significance threshold set at p < 0.05 and 95% confidence intervals RESULTS: The ulnar side of the proximal interphalangeal joint in digits 2 and 3 showed higher prevalence of osteoarthritis (59.31% ± 15.48%) than the radial side (40.68% ± 15.48%), p = 0.007; in contrast, for digits 4 and 5, prevalence was greater on the radial (54.3% ± 10.99%) than the ulnar side (45.7% ± 10.99%), p = 0.007. No significant differences were noted in osteoarthritis distribution between the radial and ulnar aspects of the metacarpophalangeal and distal interphalangeal joints.
CONCLUSIONS: This study identified distinct patterns of osteoarthritis distribution in long-finger joints, with greater prevalence in the proximal interphalangeal joints. Although there were differences between stable (digits 2 and 3) and mobile (digits 4 and 5) fingers, further research is necessary to conclusively determine the role of biomechanical forces in the development of osteoarthritis. These findings lay the groundwork for future studies of the pathophysiology of osteoarthritis in the hand, and could guide the development of preventive and therapeutic interventions.
The invention discloses a preparation method of the traditional Chinese medicine of treating coronary heart disease, the principal character is that: the invention adopts seven traditional Chinese medicinal materials such as sandalwood, lignum acronychiae, Kaempferia galanga L, nutmeg, radices salviae miltiorrhizae, fructus and sea backthern as the raw materials. First, lignum acronychiae, Kaempferia galanga L, nutmeg, are ground into thin powder and sterilize. Second, radices salviae miltiorrhizae, fructus and sea backthern are extracted for three times to combine the filtrate, recover ethanol, reduce pressure, contract, discharge ingredients and recover paste. Third, the thick paste is arranged inside the vacuum dryer to dry the paste into dry paste and ground into thin powder. The powder is evenly mixed with the thin powder of sandalwood, lignum acronychiae, Kaempferia galanga L, nutmeg to be dried in low temperature, pressed into tablets and coated with a film. The traditional Chinese medicine made by the unique technology and ingredients has fine curative effects to coronary heart disease and the functions of promoting blood circulation by removing blood stasis and reinforce heart and relieve pain, in particular the prominent lenitive effects to the symptoms of palpitations and angina.
This test is in the new type of coronavirus infection therapy and 10 (trial version) "and" new coronavirus pneumonia antiviral drug clinical trial technical guidelines (try out) ", on the basis of according to the results of the phase I and phase II clinical study to set up an experimental group and a placebo group, experimental group on the basis of medicines for load test, The control group was loaded with placebo as the base treatment. A planned cohort of 144 patients with Post-COVID-19 (120 +20% dropped out) was randomly assigned in a 1:1 ratio to the experimental group or the placebo group. Mepozumab or placebo was intravenously infused at a dose of 0.2 mg/kg on day 1 (D0). If the clinical symptoms of Post-COVID-19 were not relieved (remission was defined as a decrease in the Post-COVID-19 composite score for at least 2 days), an additional dose of 0.2 mg/kg was administered on day 7 after the first dose, and the actual dose was calculated according to the body weight of the subject. The participants were asked to record the clinical symptoms of Post-COVID-19 daily during the trial. The absent clinical symptoms were evaluated as "zero (none)", and the present clinical symptoms were recorded until they returned to normal (score: zero), which lasted for at least 2 days. On the 28th day (D28±3) after the first dose, the subjects were required to return to the study center again, return their diary cards, and complete each exit examination. If a participant stops the trial early for various reasons, laboratory testing is required to complete the efficacy and safety assessment. During the trial, the subjects were treated according to the type and severity of adverse events according to the clinical diagnosis and treatment standards.
The patients in this group will exercise for 14 weeks. It is a combination of strength and aerobic exercise.
BACKGROUND: Determination of a drug's potency in blocking the hERG channel is an established safety pharmacology study. Best practice guidelines have been published for reliable assessment of hERG potency. In addition, a set of plasma concentration and plasma protein binding fraction data were provided as denominators for margin calculations. The aims of the current analysis were five-fold: provide data allowing creation of consistent denominators for the hERG margin distributions of the key reference agents, explore the variation in hERG margins within and across laboratories, provide a hERG margin to 10 ms QTc prolongation based on several newer studies, provide information to use these analyses for reference purposes, and provide recommended hERG margin 'cut-off' values.
METHODS: The analyses used 12 hERG IC50 'best practice' data sets (for the 3 reference agents). A group of 5 data sets came from a single laboratory. The other 7 data sets were collected by 6 different laboratories.
RESULTS: The denominator exposure distributions were consistent with the ICH E14/S7B Training Materials. The inter-occasion and inter-laboratory variability in hERG IC50 values were comparable. Inter-drug differences were most important in determining the pooled margin variability. The combined data provided a robust hERG margin reference based on best practice guidelines and consistent exposure denominators. The sensitivity of hERG margin thresholds were consistent with the sensitivity described over the course of the last two decades.
CONCLUSION: The current data provide further insight into the sensitivity of the 30-fold hERG margin 'cut-off' used for two decades. Using similar hERG assessments and these analyses, a future researcher can use a hERG margin threshold to support a negative QTc integrated risk assessment.
Duchenne muscular dystrophy (DMD) is a fatal genetic neuromuscular disorder, characterised by progressive decline in skeletal muscle function due to the secondary consequences of dystrophin deficiency. Weakness extends to the respiratory musculature, and cardiorespiratory failure is the leading cause of death in men with DMD. Intermittent hypoxia has emerged as a potential therapy to counteract ventilatory insufficiency by eliciting long-term facilitation of breathing. Mechanisms of sensory and motor facilitation of breathing have been well delineated in animal models. Various paradigms of intermittent hypoxia have been designed and implemented in human trials culminating in clinical trials in people with spinal cord injury and amyotrophic lateral sclerosis. Application of therapeutic intermittent hypoxia to DMD is considered together with discussion of the potential barriers to progression owing to the complexity of this devastating disease. Notwithstanding the considerable challenges and potential pitfalls of intermittent hypoxia-based therapies for DMD, we suggest it is incumbent on the research community to explore the potential benefits in pre-clinical models. Intermittent hypoxia paradigms should be implemented to explore the proclivity to express respiratory plasticity with the longer-term aim of preserving and potentiating ventilation in pre-clinical models and people with DMD.
Risk of Seizures

The reversal of benzodiazepine effects may be associated with the onset of seizures in certain high-risk populations. Possible risk factors for seizures include: concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration in overdose cases, or concurrent cyclic antidepressant poisoning.

Flumazenil is not recommended in cases of serious cyclic antidepressant poisoning, as manifested by motor abnormalities (twitching, rigidity, focal seizure), dysrhythmia (wide QRS, ventricular dysrhythmia, heart block), anticholinergic signs (mydriasis, dry mucosa, hypoperistalsis), and cardiovascular collapse at presentation. In such cases flumazenil should be withheld and the patient should be allowed to remain sedated (with ventilatory and circulatory support as needed) until the signs of antidepressant toxicity have subsided. Treatment with flumazenil has no known benefit to the seriously ill mixed-overdose patient other than reversing sedation and should not be used in cases where seizures (from any cause) are likely.

Most convulsions associated with flumazenil administration require treatment and have been successfully managed with benzodiazepines, phenytoin or barbiturates. Because of the presence of flumazenil, higher than usual doses of benzodiazepines may be required.

Hypoventilation

Patients who have received flumazenil for the reversal of benzodiazepine effects (after conscious sedation or general anesthesia) should be monitored for resedation, respiratory depression, or other residual benzodiazepine effects for an appropriate period (up to 120 minutes) based on the dose and duration of effect of the benzodiazepine employed.

This is because flumazenil has not been established in patients as an effective treatment for hypoventilation due to benzodiazepine administration. In healthy male volunteers, flumazenil is capable of reversing benzodiazepine-induced depression of the ventilatory responses to hypercapnia and hypoxia after a benzodiazepine alone. However, such depression may recur because the ventilatory effects of typical doses of flumazenil (1 mg or less) may wear off before the effects of many benzodiazepines. The effects of flumazenil on ventilatory response following sedation with a benzodiazepine in combination with an opioid are inconsistent and have not been adequately studied. The availability of flumazenil does not diminish the need for prompt detection of hypoventilation and the ability to effectively intervene by establishing an airway and assisting ventilation.

Overdose cases should always be monitored for resedation until the patients are stable and resedation is unlikely.